{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-125505","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.394755+00:00","generated_at":"2026-05-29T09:14:09.990905+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Armata Pharma CMO Mina Pastagia departs; separation agreement provides 12-month salary continuation","bullets":["Dr. Mina Pastagia terminated as Chief Medical Officer effective Nov 13, 2024; separation agreement executed Dec 2, 2024.","Agreement provides 12 months of base salary continuation, paid in equal installments starting ~60 days post-termination.","All unvested stock options and restricted stock units forfeited; vested options must be exercised within 90 days of separation.","Pastagia releases all claims against the company in exchange for the severance benefits."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-125505","json":"https://secwatch.observer/filing/0001104659-24-125505.json","markdown":"https://secwatch.observer/filing/0001104659-24-125505.md","text":"https://secwatch.observer/filing/0001104659-24-125505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465924125505/0001104659-24-125505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465924125505/tm2430081d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:14:09.990905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}